The Patent Finder

Cellivery Therapeutics, Inc.

10 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jul 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 18, 2026
  • 1 fee due Feb 20, 2027
    The maintenance fee for Cell-Permeable (ICP)-SOCS3 Recombinant Protein and Uses Thereof (US 10,385,103) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
  • 1 fee due Jun 17, 2027
    The maintenance fee for Cell-Permeable Reprogramming Factor (ICP-RF) Recombinant Protein and Use Thereof (US 10,508,265) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

PatentTitleStatus Expires Confidence
US 10,662,419Cell-permeable (ICP) parkin recombinant protein and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,323,063Advanced macromolecule transduction domain (aMTD) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of aMTDs comprising the same, method to develop the aMTD sequences comprising the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,385,103Cell-Permeable (ICP)-SOCS3 Recombinant Protein and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,508,265Cell-Permeable Reprogramming Factor (ICP-RF) Recombinant Protein and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,774,123Cell-Permeable Bone Morphogenetic Protein (CP-BMP) Recombinant Protein and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,781,241Cell-Permeable (ICP)-SOCS3 Recombinant Protein and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,787,492Cell-Permeable (ICP)-SOCS3 Recombinant Protein and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,323,072Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,689,424Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,669,531Cell-permeable Cre (iCP-Cre) recombinant protein and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 10: 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 abandoned · 5 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited